Immune responses to borrelial VlsE IR6 peptide variants

Sillanpää, Heidi; Lahdenne, Pekka; Sarvas, Heikki; Arnež, Maja; Steere, Allen C.; Peltomaa, Miikka; Seppälä, Ilkka

doi:10.1016/j.ijmm.2006.09.001

Cited by 36 publications

(41 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Generally, seropositivity for the different IR 6 peptides corresponded well to recent findings in Finnish patients with EM (Sillanpää et al, 2007). However, seropositivity for the C6 peptide was 36% at presentation in this study compared to 55% and 65% in Finnish and Slovenian patients with EM at diagnosis and to 91% in early localised LB in Dutch patients (Sillanpää et al, 2007;Smismans et al, 2006).…”

Section: Discussionsupporting

confidence: 90%

“…However, seropositivity for the C6 peptide was 36% at presentation in this study compared to 55% and 65% in Finnish and Slovenian patients with EM at diagnosis and to 91% in early localised LB in Dutch patients (Sillanpää et al, 2007;Smismans et al, 2006). The variation in the C6 seropositivity rates between different studies may be related to differences in the patient material or timing of sampling.…”

Section: Discussioncontrasting

confidence: 58%

“…Clinical data was recorded in a study protocol and serum samples were drawn at the first consultation (sample I), at 2-3 months (sample II) and 6 months (sample III), see Table 1 and Table 2. (Sillanpää et al, 2007, Table 3). In order to facilitate for the reader, the naming of the three IR 6 peptides has been kept the same in this study.…”

Section: Methodsmentioning

confidence: 99%

“…It was not fully comparable to the kit available on the market at the time of submission, where conjugated goat-anti-human IgG/IgM was used in the detection step. The IR 6 peptide antibody assays were performed as previously described (Heikkilä et al, 2003;Sillanpää et al, 2007). Sera from the 148 patients with EM and blood donor sera (n=200) were also analysed by an independent Western Blot kit (EcoLine, Virotech, Germany) in order to exclude seropositive samples when calculating cut-off levels for the different IR 6 peptides and an alternative comparable cut-off level for the C6 peptide.…”

Section: Methodsmentioning

confidence: 99%

“…Recently, a commercial ELISA using a synthetic 26-mer peptide antigen called C6 has been evaluated and introduced in the serodiagnosis of LB (Cinco and Murgia, 2006;Smismans et al, 2006;Nyman et al, 2006;Tjernberg et al, 2007;Sillanpää et al, 2007). The C6 antigen is based on the sixth invariant region (IR 6 ) of the variable major protein-like sequence, expressed (VlsE) by B. garinii (Liang et al, 1999).…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Antibody responses to borrelia IR6 peptide variants and the C6 peptide in Swedish patients with erythema migrans

Tjernberg

Sillanpää

Seppälä

et al. 2009

International Journal of Medical Microbiology

View full text Add to dashboard Cite

The aim of this study was to evaluate the antibody responses to different VlsE protein IR6 peptide variants and the synthetic C6 peptide in acute and convalescent (2-3 and 6 months) serum samples from Swedish patients with clinical erythema migrans (EM). Serum samples were prospectively collected from 148 patients with EM and compared to serum samples obtained from 200 healthy blood donors. The IgG responses to 3 IR6 peptide variants originating from Borrelia burgdorferi (B. burgdorferi) sensu stricto, B. garinii, and B. afzelii were measured by enzyme-linked immunosorbent assays (ELISAs) and compared to a commercial C6 peptide ELISA. Seropositivity rate in the IR6 or C6 peptide ELISAs ranged from 32% to 58% at presentation, 30-52% after 2-3 months, and 20-36% after 6 months. At presentation, positive antibodies in any of the 4 ELISAs were found in 66%. In 7/52 (13%), C6-negative EM cases, serological reaction was found to the B. burgdorferi sensu stricto-derived IR6 peptide. In patients reporting previous LB compared to those without previous LB, significantly higher seropositivity rates were noted for all IR6 peptides, but not for the C6 peptide. In the serology of EM in Europe, C6 ELISA does not seem to cover all cases. An ELISA using a mixture of B. burgdorferi sensu stricto IR6 peptide and the C6 peptide could be of value in the serodiagnosis of LB in Europe. Further studies on combinations of variant IR6 peptides and the C6 peptide in other manifestations of LB are needed to address this issue.Original Publication:Ivar Tjernberg, H. Sillanpaa, I. Seppala, I. Eliasson, Pia Forsberg and P. Lahdenne, Antibody responses to borrelia IR6 peptide variants and the C6 peptide in Swedish patients with erythema migrans, 2009, International Journal of Medical Microbiology, (299), 6, 439-446.http://dx.doi.org/10.1016/j.ijmm.2008.10.006Copyright: Elsevier Science B. V. Amsterdamhttp://www.elsevier.com

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussioncontrasting

confidence: 58%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%